Brief: Lyell Immunopharma Announces CGMP Qualification Of Lyfe Manufacturing Center
15/12/2021 21:43
Dec 15 (Reuters) - Lyell Immunopharma Inc LYEL.O :
* LYELL IMMUNOPHARMA ANNOUNCES CGMP QUALIFICATION OF LYFE™
MANUFACTURING CENTER IN ADVANCE OF INITIATING CLINICAL PROGRAMS
Source text for Eikon: ID:nGNX6prMMy
Further company coverage: LYEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma